Source: GlobalData
Diagnosed incident cases of B-cell non-Hodgkin’s lymphoma to reach nearly 230,000 in 2033 across 7MM, says GlobalData
Posted in Pharma
The diagnosed incident cases of B-cell non-Hodgkin’s lymphoma (B-cell NHL) in the seven major markets (7MM*) are projected to increase from 200,844 in 2023 to 229,804 in 2033, with an annual growth rate (AGR) of 1.44%, while five-year diagnosed prevalent cases will increase from almost 634,000 to over 714,000 at an AGR of 1.26%, forecasts GlobalData, a leading data and analytics company.
GlobalData’s latest report “B-Cell Non-Hodgkin’s Lymphoma: Epidemiology Forecast to 2033,” estimates that in 2033, the US will have the highest number of diagnosed incident cases of B-cell NHL across the 7MM with over 106,600 cases, whereas Spain will have the lowest number with approximately 9,500 cases. Similarly, the US is projected to have the highest number of five-year diagnosed prevalent cases at almost 356,600 compared to Spain with lowest number of cases at nearly 28,000.
Zachary Natale, MPH, Senior Epidemiologist at GlobalData, says: “Despite the progress that has been made, B-cell NHL remains a complex spectrum of malignant neoplasms, each of which exhibits idiosyncratic clinical manifestations and behaviors.”
Though early detection and improved therapeutics have improved the prognosis for countless B-cell NHL patients, its wide-ranging clinical courses on account of subtype-specific disease behaviors and treatments makes B-cell NHL a challenging cancer to manage, especially among less prominent subtypes such mantle cell lymphoma.
Natale concludes: “Due to its heterogenous impact on the clinical course of patients, it is imperative for healthcare workers, public health professionals, and researchers to develop a more nuanced understanding of B-cell NHL’s subtypes to best address them as respective diseases.”
*7MM: The US, 5EU (France, Germany, Italy, Spain, the UK) and Japan.